Drug Trial Radar · NCT02135419
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
Last checked: Nov 19, 2026Latest source record: Jul 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,446
Actual
Start
Sep 24, 2014
Primary completion
Aug 6, 2021
Study completion Mar 31, 2024
Sponsor
- Lead sponsor
- AIDS Malignancy ConsortiumResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); The Emmes Company, LLC; University of Arkansas; University of California, San Francisco; University of Arizona
- First posted
- May 12, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The randomized phase of the trial compared topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL). Anal HSIL is tissue in the anal canal that has been damaged by infection with human papillomavirus (HPV) and is at risk for turning into anal cancer. The ANCHOR Data Safety Monitoring Board (DSMB) determined that the primary study endpoint was completed, based on the data and statistical analysis presented to them on 07SEP2021. In the post-randomization phase of this trial, all enrolled participants are offered treatment for HSIL and/or follow-up, at the participant's choice.
Conditions
- Anal Cancer
- High-grade Squamous Intraepithelial Lesion
- HIV Infection
- Human Papilloma Virus Infection
Interventions
imiquimodDrug
Applied topically
fluorouracilDrug
Applied topically
infrared photocoagulation therapyDevice
Undergo infrared coagulation
thermal ablation therapyDevice
Undergo hyfrecation/electrocautery therapy
laser therapyDevice
Undergo laser therapy
clinical observationOther
Undergo active monitoring (High Resolution Anoscopy \[HRA\]) with biopsies
laboratory biomarker analysisOther
Correlative studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Anal Cancer IncidenceTime frame: Time from randomization to diagnosis of anal cancer, assessed up to 5 years post randomization
Locations
25 sites in 2 countries. Site status is shown where the registry gives one.
UCLA CARE Clinic
Los Angeles, California
UCLA School of Nursing
Los Angeles, California
DAP Health
Palm Springs, California
University of California at San Francisco Anal Dysplasia Clinic
San Francisco, California
University of Colorado Hospital
Aurora, Colorado
Denver Public Health
Denver, Colorado
Capital Digestive Care
Washington D.C., District of Columbia
Dupont Circle Physicians Group
Washington D.C., District of Columbia
ACC Clinic, Jackson Hospital
Miami, Florida
University of Miami Miller School of Medicine - Sylvester Cancer Center
Miami, Florida
Grady Health System
Atlanta, Georgia
Anal Dysplasia Clinic MidWest
Chicago, Illinois
University Medical Center New Orleans
New Orleans, Louisiana
CrescentCare Health
New Orleans, Louisiana
Boston Medical Center
Boston, Massachusetts
Fenway Health
Boston, Massachusetts
Rutgers University New Jersey Medical School
Newark, New Jersey
Cornell Clinical Trials Unit, Chelsea Center
New York, New York
Laser Surgery Care
New York, New York
Montefiore - Albert Einstein College of Medicine
The Bronx, New York
Wake Forest Baptist Health
Winston-Salem, North Carolina
Virginia Mason Medical Center
Seattle, Washington
Harborview Medical Center
Seattle, Washington
The Polyclinic
Seattle, Washington
University of Puerto Rico
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.